Kevin Grogan

Following a huge sell-off at the start of the month, the French firm's stock has surged as investors regain confidence in the oral miR-124 enhancer's benefit-risk profile as a treatment for ulcerative colitis.

The French drugmaker expands its rare disease portfolio to include the Swiss biotech's post-transplant infection therapy potravitug in an area with no approved treatments.

The Basel-based group says that the KRAS G12C inhibitor showed clinically meaningful improvements in progression-free survival compared with Amgen's Lumakras and BMS's Krazati in non-small cell lung cancer patients. But other rivals loom.

The last few years have been characterized by challenging financing conditions in Europe, especially for biotechs in the genetic medicines field, but France's Cyllene Therapeutics has bucked the trend with a significant raise.

CEO Jane Osbourn tells Scrip a £25m investment from the British Business Bank is further validation of the sustainable, long-term potential of the firm's drug discovery platform which will allow Alchemab to grow and thrive in its home country.

The UK giant is unsurprisingly terminating the companies' $2.2bn biobucks pact based on latozinemab and nivisnebart which have both failed clinical trials.

The German group has partnered with the asset management group to establish a new entity for its long-acting contraceptives business.

The Danish firm is hoping to challenge the dominance of Roche's blockbuster Hemlibra for hemophilia A with or without inhibitors.

Another approval in a niche market will help the PD-1 immunotherapy hit its £2bn peak sales target.

Abivax, riding a $920m public offering and regulatory momentum for obefazimod, has teamed up with fellow French RNA biotech Valerio Therapeutics in an immune-mediated inflammation collaboration worth up to €2.4m upfront.